This article is mentioned in:

Introduction

Surgical resection is considered to be the only effective treatment for localized renal cell carcinoma (RCC). However, 20–40% of surgically treated patients experience recurrence of the disease (1,2). Moreover, up to 30% of patients with RCC present with metastatic disease (2,3). Immunotherapies using interferons and interleukin-2 have been used for advanced RCC since this tumor is unresponsive to radiotherapy and also refractory to chemotherapy (4). However, the two therapies, alone and in combination, have demonstrated disappointing success rates of 20% or lower (2,4). Up to 80% of clear cell RCC, the most common histological subtype of RCC, show inactivation of the von Hippel-Lindau gene (VHL) that regulates the expression of hypoxia-inducible factor-1α (HIF-1α) (2,4,5). Inactivation of VHL upregulates HIF-1α production, leading to the activation of various genes containing hypoxia response elements, including the vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), epidermal growth factor receptor type 1, transforming growth factor-α and glucose transporter genes (5,6). Molecular targeting agents such as sunitinib and sorafenib that target receptor protein-tyrosine kinases, including VEGF and PDGF receptors, were shown to be effective as first- or second-line treatment for metastatic RCC (1,2,4,5). These agents exhibit anti-tumor activities mainly by inhibiting neovascular formation via the VEGF and PDGF pathways.

Hypoxia-inducible protein 2 (HIG2), a novel hypoxia inducible gene, is expressed exclusively in RCC. Inhibition of the HIG2 expression by small-interfering RNA significantly suppresses the growth of human RCC cells (7). The addition of polyclonal anti-HIG2 antibody to culture medium induces apoptosis in RCC cell lines. By contrast, the addition of HIG2 protein to culture medium enhances the growth of human RCC cells. These findings indicate that HIG2 is an essential growth factor for RCC. Moreover, HIG2 expression is not regulated by VHL. In RCC, the absence of VHL mutation is associated with a more advanced tumor and a poorer prognosis (8,9). Molecular-targeting agents used for advanced RCC exhibit anti-tumor activity mainly via suppression of the VHL/HIF-1α pathway (1,4,5,10). Toxicities by these agents are caused by suppression of the signal transduction that is essential for the maintenance of various organ conditions. HIG2 expression is minimal or absent in normal human organs including the liver, heart, kidney, lung prostate and spinal cord (7). In addition, HIG2 expression is observed exclusively in RCC tissues. These observations suggest that HIG2 is a candidate target for the development of molecular-targeting therapy for advanced RCC. However, few studies have examined the expression of HIG2 mRNA and protein in RCC tissues, and the little available data are restricted to clear cell RCC including the granular type (7). This study aimed to elucidate HIG2 expression in a variety of RCC histological types and analyze the correlation between HIG2 expression and clinicopathological findings or patient survival.

Materials and methods

Tissue samples and patients

This study was conducted after approval by the institutional review board was obtained. A total of 93 surgical specimens of primary RCC were obtained from 65 males and 28 females who underwent radical nephrectomy between January 1991 and December 2001 at the Department of Urology, Iwate Medical University School of Medicine, Japan. The median age of these patients was 62.5 years (range 35–87). A total of 20 normal renal tissue samples were obtained from nephrectomies for localized RCC (pT1) as controls. For histological and immunohistochemical analysis, the renal tissue samples were fixed in 20% buffered formalin, embedded in paraffin and cut into 3-μm sections. The sections were stained with hematoxylin and eosin for routine histological examination. Table I shows patient characteristics, including gender distribution, age, pathological stage, nuclear grade, lymph node metastasis and distant metastasis. Tumor staging was performed according to the TNM classification of malignant tumors (11). Nuclear grading was determined based on the General Rules for Clinical and Pathological Studies on Renal Cell Carcinoma as proposed by Fuhrman (11). The pathological stage was pT1a in 22 tumors, pT1b in 27, pT2 in 19, pT3a in 8, pT3b in 16 and pT4 in 1 tumor. Lymph node metastasis was found in 9 patients. Distant metastases were found in 9 patients (lung, 7; bone, 1 and liver, 1). The tumor grade was G1 in 25 cases, G2 in 62 and G3 in 6. The histological type was clear cell in 80 tumors including 6 tumors of the granular cell, papillary in 7, cyst-associated in 3, chromophobe in 1 and spindle in 2. No patient received systemic immunotherapy prior to the nephrectomy.

Table I Patient and tumor characteristics.

Table I

Patient and tumor characteristics.

No. of patients	93
Male/female	65/28
Age (years)
Median (range)	62.5 (35–87)
Tumor stage
pT1a	22
pT1b	27
pT2	19
pT3a	8
pT3b	16
pT4	1
Lymph node status
N0	62
N1 or pN2	9
NX	22
Distant metastasis
M0	84
M1	9
Site of metastasis
Lung	7
Lung and brain	1
Bone	1
Nuclear grade
G1	25
G2	62
G3	6

Immunohistochemistry

Rabbit anti-human HIG2 antibody was used in the immunohistochemical analysis (7). Serial 3-μm sections cut from paraffin-embedded specimens were deparaffinized in xylene, rehydrated in graded ethanol and immersed in 100% methanol with 0.3% hydrogen peroxide to block endogenous peroxidase activity. The sections were treated with 10% normal goat serum, then incubated with primary antibodies overnight at 4°C. The optimal dilution of the primary antibody for HIG2 was 1:200. The sections were washed and incubated with peroxidase-conjugated goat anti-rabbit immunoglobulin (Envision+, Dako) for 30 min at room temperature. Peroxidase activity was detected by incubation in 3,3′-diaminobenzidine tetrahydrochloride solution (DAB+ liquid system, Dako). Sections were then counterstained with hematoxylin. No immunoreactivity was noted in the negative-control slides stained with immunoglobulin fraction from normal rabbit serum used instead of antibody.

Quantitative analysis of immunohistochemical staining

For each tumor specimen, at least 20 high-power fields were examined, and ~1,000 tumor cells per specimen were counted. For semi-quantitative analysis, the amount of HIG2-positive cells was calculated and expressed as labeling index (LI). The distribution of immunostaining was graded as negative (no staining or LI <10), focal (LI 10–25), regional (LI 26–50) or diffuse (LI >50).

Statistical analysis

Cancer-specific survival was shown as Kaplan-Meier survival curves. The differences between groups were analyzed using Mann-Whitney U or Kruskal-Wallis tests. P<0.05 was considered to be statistically significant. Statistical analysis was performed using statistical software (StatView version 5.0, SAS Institute, Inc. NC, USA).

Results

Immunohistochemical staining for HIG2

In normal kidney tissues only faint staining for HIG2 was observed (Fig. 1A). Positive staining for HIG2 was observed in 80/93 RCC tissues (86%) (Fig. 1B-F). In clear cell RCC, 68/80 cases (85%) showed positive staining for HIG2. Among clear cell RCC, 6 tumors were granular type. The granular cell RCC expressed HIG2. The papillary, cyst-associated and chromophobe RCC showed positive staining for HIG2 (Table II). The mean LI were 39, 66.8, 12.1, 45.4 and 24.8 in clear cell, papillary, chromophobe, spindle cell and cyst-associated RCC, respectively (Table III). The mean LI in granular type RCC was 39.

Figure 1 Immunohistochemical staining of HIG2 in (A) normal kidney tissue and (B-F) RCC tissues. (A) HIG2 expression is rarely observed in normal kidney tissue. (B) Positive staining of HIG2 in clear cell RCC. (C) Negative control of a clear cell RCC section. (D) Positive staining of HIG2 in papillary RCC. (E) Positive staining in chromophobe RCC. (F) Positive staining in spindle cell RCC. (Magnification, ×200).

Table II Positive staining for HIG2 according to the histological type.

Table II

Positive staining for HIG2 according to the histological type.

Histological type	Percent HIG2-positivity
Clear cell carcinoma	85 (68/80)
Papillary cell carcinoma	100 (7/7)
Chromophobe cell carcinoma	100 (1/1)
Spindle cell carcinoma	50 (1/2)
Cyst-associated RCC	100 (3/3)

Table III HIG2 labeling indices (LI) according to histological type.

Table III

HIG2 labeling indices (LI) according to histological type.

Histological type	LI % (mean ± SD)
Clear cell carcinoma	39.0 ± 2.98
Papillary cell carcinoma	66.8 ± 11.0
Chromophobe cell carcinoma	12.1
Spindle cell carcinoma	45.4
Cyst-associated RCC	24.8 ± 1.63

HIG2 expression and clinicopathological data

No significant difference in positive staining for HIG2 was detected between male and female patients (Table IV). Positive staining for HIG2 increased with increasing pathological stage or nuclear grade (p<0.001 and p<0.006, respectively). Moreover, a significantly higher percentage of HIG2-positive staining was observed in RCC that metastasized to the lymph node compared to that which did not metastasize (p<0.02).

Table IV HIG2 expression and clinopathological data.

Table IV

HIG2 expression and clinopathological data.

	Total no. of patients	No. of patients with each grade of HIG2 expression
		Negative	Weak	Moderate	Strong	p
Gender						0.49
Male	65	8	12	24	21
Female	28	5	6	9	8
T stage						<0.001
pT1	49	7	9	22	11
pT2	19	2	6	4	7
pT3	24	4	3	7	10
pT4	1	0	0	0	1
LN status						<0.02
LN−	62	11	16	19	16
LN+	9	0	0	3	6
LNx	22	2	2	11	7
Nuclear grade						<0.006
G1	25	6	8	8	3
G2	62	6	10	25	21
G3	6	1	0	0	5

HIG2 expression and patient survival

The 5-year cancer-specific survival rate was 81%. Patients with RCC showing negative HIG2 immunostaining exhibited an apparently higher 5-year cancer-specific survival rate compared to those with RCC showing positive staining for HIG2 (5-year cancer-specific survival was 91.7% in HIG2-negative RCC vs. 93.3, 71.4 and 58.3% in focal, regional and diffuse HIG2-positive RCC, respectively, although no significant difference was detected) (Fig. 2).

Figure 2 Kaplan-Meier survival plot showing cancer-specific survival in relation to the distribution of HIG2 staining in patients with renal cell carcinoma.

Discussion

An understanding of the biology and genetics of RCC is a key stage in the development of targeted therapeutic approaches for advanced RCC (1,2,4,5,10). The molecular targeted therapeutic agents sunitinib and sorafenib have been shown to improve progression-free survival in patients with metastatic RCC (1,2,4,5,10). Recent reports described a survival benefit associated with other targeted agents including bevacizumab, axitinib, temsirolimus and everolimun in these patients (10). The main targets of these agents are VHL/HIF-1α and related pathways (1,2,4,5,10). On the other hand, HIG2 is an essential growth factor for RCC, and plays a critical role in the development and progression of RCC via activation of the Wnt signaling pathway (7). Since over-expression of HIG2 has been demonstrated in RCC tumors with and without VHL inactivation, HIG2 expression is considered to be indirectly regulated by the VHL mutation or deletion (7). In this study, the HIG2 protein was expressed in various subtypes of RCC tumors. In addition, a significantly higher percentage of HIG2-positive staining was associated with a high pathological stage, advanced nuclear grade and lymph node metastasis, which indicate a poor prognosis. In the present as well as previous studies (7), HIG2 expression was barely detectable in adult normal kidney tissues. In addition, immunostaining for HIG2 in other adult human tissues is minimal or absent (7). Using RT-PCR analysis, a HIG2 mRNA expression is absent or scarcely detectable in tumors of other organs, including colorectal, breast and hepatocellular cancers (7). These findings suggest that HIG2 is a promising candidate for the development of molecular-targeted therapy for patients with advanced RCC. Since HIG2 promotes carcinogenesis via pathways not involving VHL/HIF-1α or its related signals, the combined use of a novel HIG2-targeting agent with existing targeted therapeutic agents such as sunitinib, sorafenib and temsirolimus is expected to have additive or synergistic anti-tumor effects on RCC.

Carbonic anhydrase IX (CAIX) is a reliable diagnostic biomarker of clear cell RCC. A low level of CAIX expression in clear cell RCC (defined as ≤85% positivity in tumor cells) has been shown to independently predict poor prognosis (3,8,12). CAIX is predominantly expressed in clear cell RCC since the expression of this molecule is regulated by the VHL/HIF-1α pathway which is disarrayed in clear cell RCC (8,13). Clinical trials of vaccination with CA9-derived peptides and administration of the cG250 monoclonal antibody, which identifies the CAIX antigen, in patients with RCC have been conducted (14,15). CAIX expression is observed in various extrarenal organs including the stomach, pancreas and small intestine (16). A high CAIX expression is considered to be a favorable prognostic marker for clear cell RCC (3,8,9). CAIX expression is low in patients with clear cell RCC associated with an aggressive clinicopathological phenotype and poor survival. In such patients, targeted therapy is usually preferred as the modality of treatment. By contrast, the HIG2 expression is rarely observed in normal organs (7). The present study showed that HIG2 expression was up-regulated in patients with aggressive RCC and a poor prognosis. Moreover, various histological subtypes of RCC showed a high HIG2 expression. Compared with CAIX, we suggest that HIG2 is a more appropriate target for molecular-targeted therapy, since there are fewer adverse effects.

In conclusion, the present study demonstrated that HIG2, an essential growth factor for RCC, was widely expressed in various subtypes of RCC including granular type, which was previously reported not to express HIG2. HIG2 expression was up-regulated in RCC and associated with an aggressive clinicopathological phenotype and poor cancer-specific survival. The findings support a previous report that proposed HIG2 as a potential target for the development of molecular-targeting therapy for advanced RCC (7).

References